Mackenzie Financial Corp Trims Holdings in Illumina, Inc. (NASDAQ:ILMN)

Mackenzie Financial Corp decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 14,095 shares of the life sciences company’s stock after selling 1,059 shares during the period. Mackenzie Financial Corp’s holdings in Illumina were worth $1,963,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System bought a new stake in Illumina during the fourth quarter valued at $3,091,000. WCM Investment Management LLC lifted its stake in Illumina by 4,288.0% during the fourth quarter. WCM Investment Management LLC now owns 144,803 shares of the life sciences company’s stock worth $20,581,000 after purchasing an additional 141,503 shares during the last quarter. Aquila Investment Management LLC lifted its stake in Illumina by 150.0% during the fourth quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company’s stock worth $3,481,000 after purchasing an additional 15,000 shares during the last quarter. Ingalls & Snyder LLC bought a new stake in Illumina during the fourth quarter worth about $2,349,000. Finally, Perigon Wealth Management LLC lifted its stake in Illumina by 3.3% during the fourth quarter. Perigon Wealth Management LLC now owns 4,414 shares of the life sciences company’s stock worth $615,000 after purchasing an additional 142 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Jacob Thaysen bought 7,330 shares of Illumina stock in a transaction on Thursday, February 22nd. The shares were purchased at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the acquisition, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.17% of the company’s stock.

Illumina Stock Up 3.5 %

Shares of NASDAQ:ILMN opened at $124.46 on Wednesday. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $229.58. The company has a market cap of $19.82 billion, a PE ratio of -16.96 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The stock’s 50-day moving average is $132.79 and its 200 day moving average is $127.58.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the business earned $0.14 EPS. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. Sell-side analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $253.00 price target on shares of Illumina in a research note on Tuesday, April 9th. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Barclays lifted their price target on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. TD Cowen downgraded Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price objective on the stock. in a report on Thursday, January 4th. Finally, HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $167.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.